Hall ET, et al. - In this systematic review, cancer patients receiving immune checkpoint inhibitors (ICIs) vs other anticancer therapies were investigated for patient-reported outcomes (PROs) and health-related quality of life (HRQoL). Screening 1453 references, researchers analyzed 15 publications representing 15 randomized controlled trials which included several cancer types (melanoma, lung cancer, genitourinary cancer, and head/neck cancer), used four different ICIs (nivolumab, pembrolizumab, atezolizumab, and ipilimumab), and compared ICIs to a wide range of therapies (chemotherapy, targeted therapies, other immunotherapy strategies, and placebo). There were only a few randomized studies that reported PROs and patient HRQoL data. As per available data, ICIs vs other anticancer therapies are well tolerated in terms of HRQoL. Given the possibility of failing to capture important symptomatology unique to ICIs with currently used instruments, a need for PROs designed specifically for ICIs is highlighted.